ES2189803T3 - Procedimiento. - Google Patents

Procedimiento.

Info

Publication number
ES2189803T3
ES2189803T3 ES94920040T ES94920040T ES2189803T3 ES 2189803 T3 ES2189803 T3 ES 2189803T3 ES 94920040 T ES94920040 T ES 94920040T ES 94920040 T ES94920040 T ES 94920040T ES 2189803 T3 ES2189803 T3 ES 2189803T3
Authority
ES
Spain
Prior art keywords
invented
controlled
methods
prepared
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920040T
Other languages
English (en)
Inventor
Nageswara R Palepu
Gopadi M Venkatesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939311188A external-priority patent/GB9311188D0/en
Priority claimed from GB939316252A external-priority patent/GB9316252D0/en
Priority claimed from GB939318920A external-priority patent/GB9318920D0/en
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2189803T3 publication Critical patent/ES2189803T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE HA INVENTADO UN PROCESO PARA PREPARA FORMULACIONES DE LIBERACION CONTROLADA DE MEDICAMENTOS PARA LA ADMINISTRACION ORAL Y FORMAS DE DOSIFICACION DE SOLIDOS DE LIBERACION CONTROLADA DE MEDICAMENTOS PREPARADOS MEDIANTE EL MISMO. PREFERIBLEMENTE, LAS FORMAS DE DOSIFICACION DE SOLIDOS DE LIBERACION CONTROLADA DE AMOXICILINA Y ACIDO CLAVULANICO ESTAN PREPARADAS DE ACUERDO CON EL PROCESO INVENTADO. TAMBIEN SE HAN INVENTADO METODOS PARA TRANSPORTAR EL CLAVULANATO Y LAS COMPOSICIONES QUE LO CONTIENEN.
ES94920040T 1993-05-29 1994-05-26 Procedimiento. Expired - Lifetime ES2189803T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939311188A GB9311188D0 (en) 1993-05-29 1993-05-29 Process
GB939316252A GB9316252D0 (en) 1993-08-05 1993-08-05 Process
GB939318920A GB9318920D0 (en) 1993-09-11 1993-09-11 Process

Publications (1)

Publication Number Publication Date
ES2189803T3 true ES2189803T3 (es) 2003-07-16

Family

ID=27266706

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94920040T Expired - Lifetime ES2189803T3 (es) 1993-05-29 1994-05-26 Procedimiento.

Country Status (13)

Country Link
EP (1) EP0701436B1 (es)
JP (1) JPH08510752A (es)
CN (1) CN1124452A (es)
AP (1) AP9400645A0 (es)
AT (1) ATE230981T1 (es)
AU (1) AU684522B2 (es)
CA (1) CA2164003A1 (es)
DE (1) DE69432015T2 (es)
ES (1) ES2189803T3 (es)
IL (1) IL109770A0 (es)
MA (1) MA23212A1 (es)
NZ (1) NZ268172A (es)
WO (1) WO1994027557A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
EP1093812A3 (en) * 1995-09-07 2001-06-06 SmithKline Beecham Corporation Amoxycillin and clavulanate containing pharmaceutical formulation
AT407701B (de) * 1996-08-12 2001-05-25 Biochemie Gmbh Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung
TWI225402B (en) 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
FR2753904B1 (fr) 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
IL131201A (en) * 1997-02-14 2005-06-19 Smithkline Beecham Lab Pharmaceutical formulations comprising amoxycillin and clavulanate
DE19705538C1 (de) * 1997-02-14 1998-08-27 Goedecke Ag Verfahren zur Trennung von Wirkstoffen in festen pharmazeutischen Zubereitungen
ES2236943T3 (es) 1997-09-19 2005-07-16 Shire Laboratories Inc. Perlas de disolucion solida.
WO1999017751A1 (en) * 1997-10-03 1999-04-15 Smithkline Beecham Corporation Controlled release solid dosage forms of lithium carbonate
BR9806280A (pt) * 1997-11-17 2000-02-15 Gist Brocades Bv Grânulos compreendendo clavulaneto e um ou mais excipientes
DK1685839T3 (da) * 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
KR100634937B1 (ko) * 1999-04-13 2006-10-17 비참 파마슈티컬스 (피티이) 리미티드 신규한 치료 방법
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US7025989B2 (en) 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
AU3986901A (en) * 2000-02-24 2001-09-03 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
AU3984101A (en) 2000-02-24 2001-09-03 Advanced Pharma Inc Antibiotic and antifungal compositions
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6991807B2 (en) 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7985420B2 (en) 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US7105174B2 (en) 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US7157095B2 (en) 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
AT413015B (de) * 2001-04-12 2005-10-15 Sandoz Ag Tablette enthaltend das k-salz der 3-(2-hydroxyethyliden)-7-oxo-4-oxa-1- azabicyclo(3.2.0)heptan-2 carbonsäure in hydrophobisierter form
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2004078164A1 (en) * 2003-03-04 2004-09-16 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP2007513143A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押出機を使用して好ましくはポロクサマーおよびグリセリドを含む多粒子アジスロマイシン組成物を製造するための噴霧凝固法
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
JP4882748B2 (ja) 2004-09-16 2012-02-22 アステラス製薬株式会社 トリアゾール誘導体またはその塩
CN107080846A (zh) 2010-07-09 2017-08-22 詹姆斯.特林卡.格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
GB201420306D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
EP3994154A1 (en) 2019-07-05 2022-05-11 GlaxoSmithKline Intellectual Property (No.2) Limited Streptomyces clavuligerus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties

Also Published As

Publication number Publication date
EP0701436A4 (en) 1997-05-21
JPH08510752A (ja) 1996-11-12
EP0701436A1 (en) 1996-03-20
DE69432015D1 (de) 2003-02-20
CA2164003A1 (en) 1994-12-08
IL109770A0 (en) 1994-11-28
WO1994027557A2 (en) 1994-12-08
WO1994027557A3 (en) 1995-03-16
EP0701436B1 (en) 2003-01-15
ATE230981T1 (de) 2003-02-15
MA23212A1 (fr) 1994-12-31
AU684522B2 (en) 1997-12-18
AP9400645A0 (en) 1994-07-31
CN1124452A (zh) 1996-06-12
NZ268172A (en) 1997-12-19
DE69432015T2 (de) 2003-11-06
AU7096294A (en) 1994-12-20

Similar Documents

Publication Publication Date Title
ITMI942484A0 (it) Composizioni farmaceutiche a rilascio controllato osmotico e per diffusione del farmaco e procedimento per la loro preparazione
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
ES2074124T5 (es) Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal.
ES2002089T3 (es) Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos.
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
DE3872739D1 (de) Arzneimittel mit langsamer freisetzung.
AU2766689A (en) New pharmaceutical formulations with programmed release
CO4750658A1 (es) Formulaciones farmaceuticas y procedimientos que comprenden amoxicilina y una sal de acido clavulanico
GR3036792T3 (en) New bi- and tricyclic aminoalcohol esters, their preparation and their use in medicaments.
WO1994027557A3 (en) Pharmaceutical thermal infusion process
DE69809074D1 (de) Herstellung von arzneimitteln
ES2067250T5 (es) Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion.
ES2038643T3 (es) Procedimiento para la obtencion de una composicion farmaceutica topica.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
IT8719064A0 (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive.
ES2037086T3 (es) Procedimiento para preparar formulaciones farmaceuticas.
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
ES2194832T3 (es) Formulaciones de ditiazem con absorcion controlada.
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
ATE21336T1 (de) Galenische form zur oralen verabreichung und verfahren zu deren herstellung.
DE58906232D1 (de) Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe.
ES2036609T3 (es) Granulado exento de aglutinante con lubricacion retardada del producto activo.
JPS5793913A (en) Enhancing agent for spermous vital power
ATE110564T1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren.
JPS5462327A (en) Remedy for dna virus infectious disease